William J. Sandborn - 08 Aug 2023 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
President and Chief Medical Officer
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Issuer symbol
VTYX
Transactions as of
08 Aug 2023
Net transactions value
-$114,810
Form type
4
Filing time
08 Aug 2023, 18:57:04 UTC
Previous filing
01 Aug 2023
Next filing
01 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Sale $68,181 -2,086 -7.5% $32.69 25,602 08 Aug 2023 By Spouse F1, F2
transaction VTYX Common Stock Sale $46,628 -1,408 -5.5% $33.12 24,194 08 Aug 2023 By Spouse F1, F3
holding VTYX Common Stock 48,389 08 Aug 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person's spouse on December 19, 2022.
F2 Represents the weighted average share price of an aggregate total of 2,086 shares sold in the price range of $32.0441 to $33.0225. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 1,408 shares sold in the price range of $33.055 to $33.37. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

President and Chief Medical Officer